Who are Placebo + Doxycycline's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Tygacil, CHLORTETRACYCLINE HYDROCHLORIDE, Doxycycline post-exposure prophylaxis, Tetracyclin ointment, Tobramycin + Dexamethasone, Tigecycline antimicrobial-lock solution.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/placebo-doxycycline.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Placebo + Doxycycline — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Placebo + Doxycycline (Placebo + Doxycycline) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: tetracycline antibiotic. Area: Infectious diseases.

phase 3 tetracycline antibiotic 30S ribosomal subunit Infectious diseases Small molecule Live · refreshed every 30 min

Target snapshot

Placebo + Doxycycline (Placebo + Doxycycline) — Hospital General de Mexicali. Doxycycline is a broad-spectrum antibiotic that inhibits protein synthesis in bacteria by binding to the 30S ribosomal subunit.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Placebo + Doxycycline TARGET	Placebo + Doxycycline	Hospital General de Mexicali	phase 3	tetracycline antibiotic	30S ribosomal subunit
Tygacil	TIGECYCLINE	Fresenius Kabi	marketed	Tetracycline-class Antibacterial [EPC]	30S ribosomal subunit	2005-01-01
CHLORTETRACYCLINE HYDROCHLORIDE	CHLORTETRACYCLINE HYDROCHLORIDE		marketed	Tetracycline	30S ribosomal subunit	1950-01-01
Doxycycline post-exposure prophylaxis	Doxycycline post-exposure prophylaxis	University of Washington	marketed	Tetracycline antibiotic	Bacterial 30S ribosomal subunit
Tetracyclin ointment	Tetracyclin ointment	University of Oslo	marketed	Tetracycline antibiotic	Bacterial 30S ribosomal subunit
Tobramycin + Dexamethasone	Tobramycin + Dexamethasone	Umm Al-Qura University	marketed	Antibiotic + corticosteroid combination	Bacterial 30S ribosomal subunit (tobramycin); glucocorticoid receptor (dexamethasone)
Tigecycline antimicrobial-lock solution	Tigecycline antimicrobial-lock solution	Clinica Universidad de Navarra, Universidad de Navarra	marketed	Tetracycline antibiotic	Bacterial 30S ribosomal subunit

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2028-10-24 — Tygacil · 8975242 · US
2029-02-05 — Tygacil · 7879828 · US
2030-10-08 — Tygacil · 8372995 · US
2033-04-07 — Tygacil · 9855335 · US

Sponsor landscape (tetracycline antibiotic class)

BioPharmX, Inc. · 2 drugs in this class
Hospital General de Mexicali · 1 drug in this class
Laboratorios Goulart S.A. · 1 drug in this class
National Taiwan University Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Placebo + Doxycycline — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-doxycycline. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing